Cesar M Compadre, University of Arkansas for Medical Sciences USA

.

Cesar M Compadre

University of Arkansas for Medical Sciences
USA


Compadre has extensive pharmaceutical research experience, on the development of bioactive compounds based on naturally occurring compounds, and on the use of molecular modeling in drug design and structure-activity studies. He has published over 80 papers and more than 70patents related to the development of bioactive compounds. He is also the developer of one FDA approved antimicrobial technology that is commercially used. He has a BSPharm degree, and obtained his Ph.D degree in medicinal chemistry and pharmacognosy, from the University of Illinois at Chicago. He conducted postdoctoral research on structure-activity relationships studies using molecular modeling at the University of Illinois working with Dr. John M. Pezzuto and at Pomona College working with Professor Corwin Hansch. Additionally, he had a sabbatical experience at NASA Ames Research Center in computer modeling. At the University of Arkansas for Medical Sciences he established and directs the molecular modeling facility. He has extensive research collaborations with many scientists locally, nationally and internationally.

Research Interest

Bioactive Natural Products, Molecular Modeling, and Ethnopharmacology Field Research

Cesar M. Compadre, Ph.D.

Professor

Office: Biomed I, Room 246
Phone: 501-686-6493
FAX: 501-686-6057
E-mail: CMCompadre@uams.edu

 https://www.researchgate.net/profile/Cesar_Compadre

 

Dr. Compadre has extensive research experience, on the study of bioactive compounds from natural origin, and on the use of molecular modeling in drug design and structure-activity studies, with over 70 publications, 9 US patents related to the development of bioactive compounds, and one FDA approved antimicrobial technology.  Dr. Compadre has BSPharm degree, and obtained his Ph.D degree in medicinal chemistry and pharmacognosy.  He conducted postdoctoral research on structure-activity relationships studies using molecular modeling at the University of Illinois and at Pomona College working with Professor Corwin Hansch. Additionally, he had a sabbatical experience at NASA Ames Research Center in computer modeling.   At the University of Arkansas for Medical Sciences he established and directs the molecular modeling core facility. He has extensive research collaborations with many scientists locally, nationally and internationally.
Dr. Compadre, coordinates and teaches the COP P3 class “Pharmacognosy and Complementary and Alternative Medicine” and  has directed or co-directed over 20 graduate students.

Professional Experience

1994 – present     Director, Biomedical Visualization Center University of Arkansas for Medical Sciences
2008 – present     Professor, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
1993 – 2008     Associate Professor Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences
1998 – 1999     Visiting Scholar, Bioinformatics Center, NASA, Ames Research Center, California
1988 – 1993     Assistant Professor, Department of Biopharmaceutical Sciences, University of Arkansas for Medical Sciences
1986 – 1988     Research Associate (Corwin Hansch), Chemistry Department, Pomona College
1985 – 1986     Research Associate (John Pezzuto) Department of Pharmacology, College of Medicine and Program for Collaborative Research in the Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago

Research experience

• Nov 1988–
  present

  Professor (Full)

  University of Arkansas for Medical Sciences · Department of Pharmaceutical Sciences
  United States
• Jul 1986–
  Oct 1988
  Pomona College
  USA · Claremont
• Oct 1985–
  Jul 1986

  Research Associate

  University of Illinois at Chicago · College of Pharmacy
  USA · Chicago
• Sep 1980–
  Nov 1988

  Graduate Student- Post-Doctoral

  University of Illinois at Chicago, College of Pharmacy
  USA · Chicago

Other

• Languages
  English, Spanish; Castilian
• Scientific Societies
  MCBIOS
  American Chemical Society
  American Association of Pharmaceutical Scientists

 


 





////////

Abdel Omri

 

Abdel Omri

Laurentian University
Canada
Abdel Omri obtained his PhD from Université de Montréal in 1996. After completing postdoctoral fellowships at McGill University and the University of Toronto (1996-1998), he spent more than 2 years as Research associate at NRC (institute of biological sciences in Ottawa) from 1998 to 2000. He is currently Full Professor in the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology, the Biomolecular Sciences PhD Programme, School of Rural and Northern Health PhD Programme. His research interests are focused on Lipid-based drug and vaccine delivery systems. His laboratory employs a multi-disciplinary approach to addressing the antimicrobial resistance to gram negative bacteria in cystic fibrosis patients and in medical devices implants. He is also involved in the education of undergraduate and graduate students through the coordination of several calendar courses in biochemistry, pharmacology and toxicology and pharmaceutical technology. In addition to research, He is actively involved in the research training of both undergraduate and graduate students. He has served in administrative capacities in several international scientific societies. He has published over 50 peer-reviewed research articles over his career on various aspects of drug delivery and targeting in addition to several published book chapters and books (2). He has served on a number of Editorial Boards and Granting Agencies in Canada and abroad. He also has 2 patents.

Research Interest

Biochemistry; Pharmacology; Toxicology; Pharmaceutical technology; Lipid-based drug and vaccine delivery systems.
 

Abdelwahab Omri 

Full Professor

Chemistry and Biochemistry
Science, Engineering and Architecture

S-416, Science Building
Sudbury Campus

705.675.1151 ext 2190

aomri@laurentian.ca

• About
• Research
• Teaching
• Publications

 https://laurentian.academia.edu/AbdelOmri

 https://www.linkedin.com/in/abdel-omri-19842811

 

Biography

Dr. Omri obtained his Ph.D. degree from the Université de Montréal, Canada, in 1995. After completing postdoctoral fellowships at McGill University and the University of Toronto (1996–1998), he spent more than 2 years as Research Associate at NRC (Institute of Biological Sciences in Ottawa) from 1998 to 2000. Dr. Omri is currently a Full Professor at the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology, the Biomolecular Sciences Ph.D. Program, School of Rural and Northern Health Ph.D. Program. His research interests are focused on lipid-based drug and vaccine delivery systems. His laboratory employs a multidisciplinary approach to addressing the antimicrobial resistance to gram negative bacteria in cystic fibrosis patients and in medical devices implants. Dr. Omri is also involved in the education of undergraduate and graduate students through the coordination of several calendar courses in biochemistry, pharmacology and toxicology, and pharmaceutical technology. In addition to research, Dr. Omri is actively involved in the research training of both undergraduate and graduate students. Dr. Omri has served in administrative capacities in several international scientific societies. He has published over 60 peer-reviewed research articles over his career on various aspects of drug delivery and targeting in addition to several published book chapters and books (2). He has served on a number of editorial boards and granting agencies in Canada and abroad. Dr. Omri has 2 patents.

Education

• Pharm B
• MSc
• PhD

Abdel Omri, Ph.D.

Northern Ontario School of Medicine, East Campus
935 Ramsey Lake Road
Sudbury ON Canada P3E 2C6
Email: aomri@nosm.ca
 

Current Position

Professor, Chemistry/Biochemistry
Cross appointed to Northern Ontario School of Medicine, Medical Sciences Division
Cross appointed to Biology, Laurentian University:
Faculty member: Biomolecular Sciences PhD program, Laurentian University
Faculty member: IRNH PhD program, School of Rural & Northern Health Laurentian University
​

Education and Training

Ph.D.  Pharmacology (Faculty of Medicine). University of Montreal, 1996
M.Sc.  Pharmacology (Faculty of Medicine). University of Montreal, 1992
B.Sc.   Pharmacy, University of Baghdad (Baghdad), 1983

Research Investigations

My current interests include:

1. Liposomal delivery of antisense oligonucleotides. Effect on P-glycoprotein function in multidrug resistant cells in vitro and in vivo studies. Cationic liposome formulations are used to promote the penetration of antisense oligonucleotides into the cell membrane and protect them from enzymatic degradation (nucleases).
2. Liposomal delivery of antimicrobial agents towards resistant bacterial pathogens: pulmonary and systemic infections. Construction of liposomes with high encapsulation efficiency, favorable antimicrobial release profile and enhanced bactericidal activity, to overcome the problem of bacterial resistance caused by low permeability of the bacterial cell envelope and by production of antimicrobial-inactivating enzymes.
3. Liposomal formulations of drugs and vaccine for oral delivery. Liposomes are used to protect the encapsulated agents from the harsh gastrointestinal milieu (low pH, phospholipases, and bile salts) and to enhance their absorption to the systemic circulation and to increase the efficacy of these agents while minimizing their frequency of administration. Special liposomal formulation will be prepared, characterized and assayed for their efficacy in vitro and in animal models.

Membership and Contributions in Professional Organizations

1. American Society for Microbiology
2. American Society of Pharmacology and Experimental Therapeutics
3. Pharmacological Society of Canada
4. Canadian Society of Pharmaceutical Sciences
5. Ordre des Pharmaciens de Tunisie

Selected Publications

Shweta Gupta, Rajesh Kesarla Abdelwahab Omri. Formulation strategies to improve the bioavailabilty of poorly absorbed drugs with special emphasis on self-emulsifying systems ISRN Pharmaceutics, 2013. In press
Moayad Alhariri, Ali O. Azghani, Abdelwahab Omri. Liposomal antibiotics for infectious diseases. Expert Opinion on Drug Delivery. 2013 Nov;10 (11): 1515-32
Adam Bignucolo, Varun P. Appanna, Sean C. Thomas, Christopher Auger, Sungwon Han, Abdelwahab Omri, Vasu D. Appanna. Hydrogen peroxide stress provokes a metabolic reprogramming in P. fluorescens: Enhanced production of pyruvate. Journal of Biotechnology. 2013 Sept; 167 (3):  309–315
Mai Alhajlan, Moayad Alhariri, Abdelwahab Omri. Liposomal Clarithromycin: Effectiveness, Safety and Modulation of Pseudomonas aeruginosa Virulence Factors. Antimicrobial Agents and Chemotherapy. 2013 Jun; 57(6):2694-704.
Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrobial Agents and Chemotherapy. 2013 Jan; 57(1): 569-78.
Linette Sande, Marisel Sanchez, Joy Montes, Andrea J. Wolf, Margie A. Morgan, Abdelwahab Omri, George Y. Liu.Liposomal Encapsulation of Vancomycin Improves Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Infection Model. Journal of Antimicrobial Chemotherapy. 2012 Sep;67(9): 2191-4.

/////////////

Ronald T. Wester, Ph.D., Head of Chemistry

 

Ronald T. Wester, Ph.D., Head of Chemistry

Ron Wester is the Head of Chemistry at Nimbus Therapeutics and has more than 25 years of leadership experience in the pharmaceutical industry. Prior to joining Nimbus, Dr. Wester was a medicinal chemistry principal investigator at Pfizer, where he discovered or co-discovered numerous clinical and preclinical candidates including Phase III CETP inhibitor torcetrapib (HDL-cholesterol elevation), Phase II NHE-1 inhibitor zoniporide (cardioprotection) and Phase II renin inhibitor terlakiren (blood pressure reduction). As Executive Director of Cardiovascular & Metabolic Diseases Medicinal Chemistry, Dr. Wester led more than 100 chemists, and was responsible for establishing and advancing a diverse portfolio of projects across six therapeutic areas (atherosclerosis, cardiovascular, diabetes, obesity, osteoporosis and frailty). He chaired the CETP Early Clinical Management Team, overcoming numerous development challenges while advancing torcetrapib through preclinical and Phase I studies. As Vice President of Exploratory Medicinal Sciences, Dr. Wester led up to 325 scientists and technology experts in providing Pfizer drug discovery projects with integrated technology support, including new lead identification, computational sciences, analytical chemistry, reagent provision, biomarker & functional genomics, and exploratory safety. During his tenure at Pfizer, Dr. Wester complemented his scientific and leadership accomplishments with extensive experience across development, in-/out-licensing, legal, finance, human resources and public policy.
He earned his Ph.D. in synthetic organic chemistry from Yale University with Professor Fred Ziegler. Dr. Wester authored or co-authored 26 scientific publications and presentations, and is an inventor on 15 issued U.S. patents.

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer

 

 

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer

Dr. Rosana Kapeller is Chief Scientific Officer of Nimbus Therapeutics and holds responsibility for advancing the company’s programs from discovery to early human proof-of-concept. In addition to spearheading Nimbus’ scientific vision, Dr. Kapeller co-led the Series A funding for the company in 2011 and has worked closely with other members of the management team to create multiple strategic business opportunities for the company, including partnerships and collaborations with Schrodinger, Monsanto, Shire and Genentech. Before joining Nimbus, Dr. Kapeller was Vice President of Research and a Co-Founder of Aileron Therapeutics, where she led the development of that company’s “Stapled Peptide” technology. Under her leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Molecular and Cellular Biology. Dr. Kapeller earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech. She currently serves as a scientific advisor to Atlas Venture.

 
 LINKS
 https://www.linkedin.com/in/rosana-kapeller-50231b

 https://twitter.com/kapellerrosana
 https://www.facebook.com/rosana.kapellerlibermann

Experience

CSO

Nimbus Discovery

February 2010 – Present (6 years 3 months)

Consultant

Third Rock Ventures

November 2009 – February 2010 (4 months)

Vice President of Research

Aileron Therapeutics

August 2005 – September 2009 (4 years 2 months)

Director

Millennium Pharmaceuticals

August 2002 – July 2005 (3 years)

Scientist/ Sr. Scientist

Millennium Pharmaceuticals

April 1996 – August 2002 (6 years 5 months)

Education

Tufts University

PhD, Molecular and Cellular Physiology

September 1987 – May 1994

UERJ

MD, Medicine

January 1980 – December 1986

 

How to Get to the Senior Levels of Scientific Management
#WESTpanel

Join us for a thought-provoking discussion on successful strategies for women in reaching top management in the sciences. A dynamic panel of women leaders will share their successes, and more importantly their lessons learned, as they have moved up the career ladder in scientific management. Come hear the wisdom of women leaders as they provide candid feedback and insightful advice on what enables women to reach the top.

Panelists: 

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer at Nimbus Therapeutics Rosana Kapeller is the Chief Scientific Officer of Nimbus Therapeutics and has more than 20 years of leadership experience in the biotechnology industry. Prior to joining Nimbus, she was Co-Founder and Vice President of Research of Aileron Therapeutics, where she led the development of Aileron’s “Stapled Peptide” technology. Under her scientific leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Department of Molecular and Cellular Biology. She earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. Dr. Kapeller has published extensively and filed more than 150 patent applications, of which 50 have been issued. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech.

///////

Donald W. Nicholson, Ph.D., Chief Executive Officer

 Donald W. Nicholson, Ph.D., Chief Executive Officer

 

Donald “Don” Nicholson is the Chief Executive Officer and Board member of Nimbus. He joined from Merck where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious diseases and neurosciences. He began his career in 1988 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, Calif., and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Dr. Nicholson has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally-recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in biochemistry from the University of Western Ontario, and trained as a Medical Research Council post-doctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

John V Schloss

 
  John V Schloss

John V Schloss has spanned professional and cultural boundaries across a diverse range of research, educational, and business activities. His accomplishments include: discovery and development of new drugs and drug-delivery systems; authoring or co-authoring issued patents covering composition of matter and use of novel drug substances; extensive managerial experience in industry and academics (Chief Executive Officer, Research Supervisor, Director, and five times as Chair of an academic department); securing major competitive research awards from the NIH, Office of Naval Research, US-Israel Binational Science Foundation, Maine Technology Institute, and the Pfeiffer Research Foundation as Principal Investigator; and obtaining funding for, building, and managing core facilities for protein sequencing and amino acid analysis, large-scale fermentation, large-scale protein purification; and mass spectrometry.
links
 https://www.researchgate.net/profile/John_Schloss2/publications
https://www.facebook.com/john.v.schloss
 jschloss@une.edu
 https://www.linkedin.com/in/john-schloss-4b381112

 

Research Interest

Epigenetic effects of nutraceuticals; The effect of nutraceuticals on drug pharmacometrics; Biomarkers of oxidative stress, with special emphasis on the transsulfuration pathway; Taurine and taurine metabolites; Glutathione.

John V. Schloss was born in St. Louis and grew up in the Midwest (Missouri, Kansas, and Oklahoma). He obtained a B.S. in chemistry and biology from the University of Tulsa in 1973 and a Ph.D. in biomedical sciences from the University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences, located within the Biology Division of Oak Ridge National Laboratory, in 1978. After conducting postdoctoral work at the University of Wisconsin in Madison (1978 _ 1981), he joined the Central Research and Development Department of E. I. du Pont de Nemours & Company, Wilmington, Delaware, in 1981. Between 1987-91, John served as research supervisor of DuPont's Enzyme Mechanisms Group. From 1991-2005, Dr. Schloss was affiliated with the Department of Medicinal Chemistry, University of Kansas in Lawrence, initially as chair (1991-94) and then professor (1991-2000) and adjunct professor (2000-05). Between 2000-03, he helped to build a new pharmacy program as part of Kuwait University's Health Sciences Center and served as chair of Pharmaceutical Chemistry. In 2002, John helped to found ThioPharma, Inc., in San Diego, which licensed its drug delivery technology to Cenomed Biosciences in 2007. While helping to establish ThioPharma, John also conducted pharmaceutics research at NeuroSystec Corporation in Valencia, California, 2004-08.

Research experience

• Aug 2003–
  Jun 2008

  CSO, CEO

  ThioPharma
  USA · San Diego
• Jun 1981–
  Jun 1991

  Research Supervisor

  Dupont · Central Research and Development
  USA · Delaware

Teaching experience

• Jul 2011–Dec 2014

  Professor and Chair

  Marshall University · Department of Pharmaceutical Science and Research
  United States
• Jun 2008–Jul 2011

  Professor and Chair

  University of New England (USA)
  United States · Biddeford
• Jun 1991–Jun 2005

  Professor

  University of Kansas · Department of Medicinal Chemistry
  USA · Lawrence

Education

• Jun 1978–Jun 1981

  University of Wisconsin, Madison

  Enzyme Mechanisms · postdoctoral research
  USA · Madison
• Jun 1973–Jun 1978

  University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences

  Biomedical Sciences · Ph.D.
  USA · Oak Ridge National Laboratory
• Jun 1969–
  Jun 1973

  University of Tulsa

  Biology and Chemistry · B.S.
  USA · Tulsa

Awards & achievements

• Jul 2010

  Grant: Cluster Initiative Program, Maine Technology Institute
• Jun 2010

  Grant: Pfeiffer Research Foundation
• Aug 2008

  Grant: Maine Technology Assest Fund
• Apr 2007

  Grant: NIH/NIDCD R43 DC0085202
• Sep 2003

  Grant: NIH/NIAAA R43 AA014566
• Jun 2003

  Grant: ONR N00014-03-1-0450
• Jun 1999

  Grant: ONR N00014-00-1-01-02
• Jun 1994

  Grant: ONR N00014-94-1-0457
• Jun 1994

  Grant: NIH/NIGMS R01 GM048568
• Aug 1990
  Award: Du Pont Agricultural Prodcuts Department, Research and Development Division Accomplishment Award
• Jun 1979

  Grant: NIH/NIGMS F32 GM006959

Other

• Scientific Societies
  American Association of Colleges of Pharmacy
  American Association of Pharmaceutical Scientists
  American Chemical Society
  American Society for Biochemistry and Molecular Biology
  International Institute for Pharmaceutical Safety
  Sigma Xi

Summary

More than 30 years of experience divided between academics and industry: discovery and development of new drugs and drug-delivery systems; issued patents covering composition of matter and use; managerial experience in academics and industry (five times as Chair, Research Supervisor, Director, and Chief Executive Officer); PI on competitive research awards from NIH, Office of Naval Research, Maine Technology Institute, and the Pfeiffer Research Foundation; obtained funding for, built, and managed core facilities for protein sequencing and amino acid analysis, large-scale fermentation and protein purification; and mass spectrometry.

Specialties: Enzyme mechanisms and biochemistry, pharmaceutical chemistry, and analytical chemistry

Experience

Researcher

Marshall University Research Corporation

September 2015 – Present (8 months)Huntington, West Virginia

Investigating the regulation of hydrogen sulfide signaling by the taurine biosynthetic pathway. Support for this project is provided by the U.S. Army through a CDMRP Discovery Award mechanism.

Professor and Chair, Pharmaceutical Science and Research, School of Pharmacy

Marshall University

August 2011 – January 2015 (3 years 6 months)

Started the basic science and research effort for a new school of pharmacy. This was the third new pharmacy program and the 4th pharmacy school that I had been associated with.

Professor and Chair

University of New England

June 2008 – August 2011 (3 years 3 months)Portland, Maine

Built the basic and clinical science component of a new college of pharmacy; PI on $4.5 million in competitive funding from the Maine Technology Institute and an award from the Gustavus & Louise Pfeiffer Research Foundation

(Open)1 recommendation

• 

  Bryon Crowder

  Founder | Wave Creator at Life Is Fluid (LIF)

  John was an invaluable resource to Life Is Fluid while at UNE. John and his team were instrumental in initial research and development and I was very impressed with the breadth of his expertise. John was always available and made the time to make...View

CEO, CSO

ThioPharma

2002 – 2008 (6 years)

Discovery-stage pharmaceutical company; became virtual in 2003; licensed technology to Cenomed Biosciences in 2007; concurrently worked as Director of Chemistry for NeuroSystec (2004-2008); PI on two SBIR grants from NIH, one from NIAAA and one from NIDCD, maintained funding from the Office of Naval Research through the University of Kansas

Professor, Medicinal Chemistry

University of Kansas, College of Pharmacy

1991 – 2005 (14 years)

Served as Chair (1991-1994) during the transition of the College of Pharmacy from a B. Pharm. to a Pharm. D. program; discovered a new class of neuroprotective drugs; helped to build a new pharmacy school in Kuwait as Chair of Pharmaceutical Chemistry (2000-2003), while maintaining and renewing research support from the Office of Naval Research through the University of Kansas; maintained tie as Adjunct Professor (2000-2005) while building the pharmacy program in Kuwait and starting ThioPharma in San Diego; continuously funded by the Office of Naval Research from 1994-2004, R01 funding from NIGMS/NIH, US-investigator on several US-Israel Science Foundation awards; elected Secretary, Biological Chemistry Division, American Chemical Society (1997-1999); elected to co-chair the Gordon Research Conference on Enzymes, Coenzymes & Metabolic Pathways (1992)

Research Supervisor, Enzyme Mechanisms

Du Pont Central Research

1981 – 1991 (10 years)

Research Supervisor, Enzyme Mechanisms Group (1987-1991); determined the enzyme site-of-action for a new class of biocides discovered by screening; determined the molecular mechanism of these biocides at the enzyme level; developed a conceptual paradigm for relative inhibitor potency at the whole organism level for different enzymes in the same metabolic pathway; recognized expert on slow-binding enzyme inhibition; co-chairman and invited speaker in a colloquium on "Slow and Tight-Binding Inhibitors of Enzymes" at the 12th International Congress of Biochemistry (1982); successful design of mechanism-based inhibitors with biological activity; Du Pont Agricultural Products Department, Research and Development Division Accomplishment Award (1990); co-organizer and co-director, NATO-ASI Summer School on "Enzymatic and Model Carboxylation and Reduction Reactions for Carbon Dioxide Utilization" (1989); co-organizer, Workshop on the Biosysthesis of Branched Chain Amino Acids, Beer Sheva, Israel (1989); discovered oxygen-consuming side reactions for three mechanistic classes of enzymes; administrative responsibility for the protein sequencing facility; built large scale (300 L) fermentation, and protein purification facilities (> $ 2 million)

Education

University of Wisconsin-Madison

Postdoc, Enzyme Mechanisms

1978 – 1981

University of Tennessee-Knoxville

Ph.D., Protein Chemistry, Biomedical Sciences

1973 – 1978

Dr John Schloss named Founding Chair of Pharmaceutical Science & Research

Friday, September 16, 2011 - 02:58 Special to HNN Provided by Marshall University

HUNTINGTON, W.Va. – Dr. John V. Schloss, an academic and industrial researcher with more than 30 years of combined experience, has been named founding chair of pharmaceutical science and research at the Marshall University School of Pharmacy. He also will serve as a member of the Pharmacy Executive Council.

“Marshall University School of Pharmacy is starting with an impressive infrastructure for teaching and research,” Schloss said. “This will be the third time I have helped start a new pharmacy program and the Marshall program has the potential to become a leader in the area of pharmacy education and pharmaceutical research. It is an exciting time to be a part of Marshall University.”

After receiving his Ph.D. from the University of Tennessee Graduate School of Biomedical Sciences, located in the Oak Ridge National Laboratory, Schloss conducted postdoctoral work in the laboratory of Prof. W. W. Cleland at the University of Wisconsin-Madison from 1978 until 1981.
Following completion of his postdoctoral work, Schloss joined the research and development division of E.I. DuPont de Nemours & Co. in Wilmington, Del., where he held positions as a principal investigator and research supervisor. While at DuPont, Schloss published nearly three dozen papers and presented at more than 60 international and national conferences.
Beginning in 1991, Schloss served as professor and chair of the department of medicinal chemistry in the University of Kansas College of Pharmacy. He maintained his affiliation with the pharmacy program in Kansas until 2005. During this time he helped develop a new pharmacy program as part of the Kuwait Health Sciences Center, while maintaining his research programs at the University of Kansas.
In 2002, Schloss co-founded ThioPharma Inc., a biotech startup company focused on discovery-stage pharmaceuticals. While managing ThioPharma from 2002 to 2008, he served as director of chemistry at NeuroSystec, another biotech startup focused on site specific drug delivery to the inner ear, and was principal investigator on two grants funded by the National Institutes of Health. One of the grants was from the National Institute on Alcohol Abuse and Alcoholism and the other was from the National Institute on Deafness and Other Communication Disorders.
Schloss’ expertise in developing a school of pharmacy was tapped again in 2008, when he joined the University of New England. As a founding faculty member and chair of the department of pharmaceutical sciences, Schloss continued his research activities while developing curriculum, recruiting faculty and teaching.
“Dr. Schloss has an extensive background in both the scholarship and discovery in pharmaceutical sciences and will provide excellent leadership for the department’s development,” Dr. Kevin Yingling, dean of the school of pharmacy, said. “He is a fantastic addition to our team and we are happy to welcome him.”

Schloss has received many honors, as well as several notable research awards and grants, including a DuPont Agricultural Products Department, Research and Development Division Accomplishment Award, a Gustavus and Louise Pfeiffer Research Foundation grant, National Institutes of Health grants, Office of Naval Research grants, US-Israel Binational Research Foundation grants and Maine Technology Institute grants. He also has provided substantial service to his profession through organizational leadership.

////////